Prevalence of Sarcopenia and Its Effect on Postoperative Complications in Patients with Crohn’s Disease

Table 1

Demographic and clinical characteristics in CD patients with or without sarcopenia.

	All patients ()	Sarcopenia ()	Nonsarcopenia ()	value
Age, years				0.985
Gender				<0.001
Male	74 (59.7)	11 (32.4)	63 (70.0)
Smoking	12 (9.7)	0 (0)	12 (13.3)	0.035
Alcohol	7 (5.6)	0 (0)	7 (7.8)	0.188
BMI				<0.001
BMI categories				<0.001
Underweight	59 (47.6)	29 (85.3)	30 (33.3)
Normal	57 (46.0)	4 (11.8)	53 (58.9)
Overweight	8 (6.5)	1 (2.9)	7 (7.8)
Skeletal muscle index (cm^2/m^2)				<0.001
Disease duration (months)				0.867
Age of onset				0.492
≤16 (A1)	9 (7.3)	4 (11.8)	5 (5.6)
17-40 (A2)	81 (65.3)	21 (61.8)	60 (66.7)
>40 (A3)	34 (27.4)	9 (26.5)	25 (27.8)
Disease location				0.063
Ileum (L1)	71 (57.3)	16 (47.1)	55 (61.1)
Colon (L2)	18 (14.5)	9 (26.5)	9 (10.0)
Ileocolon (L3)	35 (28.2)	9 (26.5)	26 (28.9)
Disease behavior				0.026
Nonstricturing, nonpenetrating (B1)	22 (17.7)	4 (11.8)	18 (20.0)
Stricturing (B2)	67 (54.0)	25 (73.5)	42 (46.7)
Penetrating (B3)	35 (28.2)	5 (14.7)	30 (33.3)
Perianal disease	34 (27.4)	13 (38.2)	21 (23.3)	0.097
HBI score				0.179
Preoperative therapy				0.712
No therapy	22 (17.7)	8 (23.5)	14 (15.6)
Steroid	20 (16.1)	6 (17.6)	14 (15.6)
5ASA	24 (19.4)	8 (23.5)	16 (17.8)
AZA	36 (29.0)	8 (23.5)	28 (31.1)
MTX	4 (3.2)	1 (2.9)	3 (3.3)
IFX	18 (14.5)	3 (8.8)	15 (16.7)
Hemoglobin (g/L)				<0.001
White cell count (cells ×109/L)				0.872
Platelet				0.128
Prealbumin (g/L)				0.030
Albumin (g/L)				0.006

BMI: body mass index; HBI: Harvey Bradshaw Index; 5-ASA: 5-aminosalicylate; AZA: Azathioprine; MTX: Methotrexate; IFX: Infliximab. values < 0.05 were highlighted in italic.